Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Apidra Increased CV Events Likely Due To Baseline Imbalance, FDA Concludes

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

The higher incidence of cardiovascular events seen with Sanofi-Aventis’ Apidra in patients with type 1 diabetes appears to have been a result of baseline imbalances, NDA review documents suggest.

You may also be interested in...

Aradigm Inhaled Insulin Type 1 Diabetes Study Raises Efficacy Concern

Novo Nordisk and Aradigm may focus on type 2 diabetes only for their AERx iDMS inhaled insulin system NN1998 following disappointing glucose suppression results in a Phase III type 1 diabetes trial.

FDA Priority Review Voucher Redemption Fee Set At $4.6 Million In FY 2011

Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011

September 2010 Approvals






Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts